Arfendazam
 |
|
|---|---|
| Systematic (IUPAC) name | |
| ethyl 7-chloro- 4-oxo- 5-phenyl- 2,3-dihydro- 1,5-benzodiazepine- 1-carboxylate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 37669-57-1 |
| ATC code | None |
| PubChem | CID 65803 |
| ChemSpider | 59219  |
| UNII | P37G7BTX8V |
| Chemical data | |
| Formula | C18H17ClN2O3 |
| Mol. mass | 344.792 |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Arfendazam is a drug which is a benzodiazepine derivative. Arfendazam is a 1,5-benzodiazepine, with the nitrogen atoms located at positions 1 and 5 of the diazepine ring, and so is most closely related to other 1,5-benzodiazepines such as clobazam.
Arfendazam has sedative and anxiolytic effects similar to those produced by other benzodiazepine derivatives, but is a partial agonist at GABAA receptors, so the sedative effects are relatively mild and it produces muscle relaxant effects only at very high doses.[1][2]
Arfendazam produces an active metabolite lofendazam, which is thought to be responsible for part of its effects.[3]
 |
This sedative-related article is a stub. You can help Wikipedia by expanding it. |
[edit] See also
[edit] References
- ^ Müller E. Benzodiazepine receptor interactions of arfendazam, a novel 1, 5-benzodiazepine. Pharmacopsychiatry 1985, (18):10-11.
- ^ Müller WE, Groh B, Bub O. In vitro and in vivo studies of the mechanism of action of arfendazam, a novel 1, 5-benzodiazepine. Pharmacopsychiatry 1986, (10):314-315.
- ^ J. Adrien, F. Albani, A. Baruzzi, M. Berger, E.O. Bixler, A.A. Borbeley, D.G. Dikeos, R. Drucker-Colin, R. Fritsch Montero, Y. Hishikawa, S. Inoue, A. Kales, E. Lugaresi, H. Merchant-Nancy, J.M. Monti. The Pharmacology of Sleep. Springer. ISBN 978-3540589617
